Smith et al. [39] studied the clinical outcomes and safety of teprotumumab, an IGF-1R inhibitory monoclonal antibody, as a treatment for thyroid-associated ophthalmopathy in 88 randomized patients aged 18–75. Here, IGF1R is linked to Graves ophthalmopathy.